SARS-CoV-2; from vaccine development to drug discovery and prevention guidelines

被引:11
|
作者
Khodavirdipour, Amir [1 ,2 ]
Keramat, Fariba [3 ]
Hashemi, Seyed Hamid [3 ]
Alikhani, Mohammad Yousef [4 ]
机构
[1] Univ Tabriz, Fac Nat Sci, Dept Biol, Tabriz, Iran
[2] St Johns Hosp, Div Human Genet, Dept Anat, Bangalore, Karnataka, India
[3] Hamadan Univ Med Sci, Fac Med, Dept Infect Dis, Hamadan, Iran
[4] Hamadan Univ Med Sci, Dept Microbiol, Hamadan, Iran
来源
AIMS MOLECULAR SCIENCE | 2020年 / 7卷 / 03期
关键词
COVID-19; vaccine; drug discovery; hrsACE2; ivermectin; famotidine; PNEUMONIA;
D O I
10.3934/molsci.2020013
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
All species of coronavirus may cause infections in birds which is known to us since the 60s, but recently, from Nov 2019, the disease emerged in humans from the seafood market in Wuhan city. The previous viral outbreaks like SARS-CoV and MERS-CoV have also shown a greater mortality rate when transmitted to humans than other animals. An emerging concern in the 2019 novel coronavirus (SARS-CoV-2) is in terms of developing vaccine or discovery of new drugs to overcome the current viral pandemic. In this rapid-review, we aim to update the available data on coronavirus with the latest findings and achievements. So far, great steps have been taken such as hrsACE2 by a Swedish team from Karolinska Institute. Monash University announced the efficacy of Ivermectin to overcome COVID-19. The CRISPR/Cas13d as a new innovative therapeutics based might overcome the challenge of COVID-19. those strains of virus which lacking E protein-encoding regions are the perfect choice for vaccine development.
引用
收藏
页码:281 / 291
页数:11
相关论文
共 50 条
  • [41] The challenge of emerging SARS-CoV-2 mutants to vaccine development
    Li, Rong
    Liu, Jun
    Zhang, Hui
    JOURNAL OF GENETICS AND GENOMICS, 2021, 48 (02) : 102 - 106
  • [42] Targets and strategies for vaccine development against SARS-CoV-2
    Malik, Jonaid Ahmad
    Mulla, Almas Hanif
    Farooqi, Tahmeena
    Pottoo, Faheem Hyder
    Anwar, Sirajudheen
    Rengasamy, Kannan R. R.
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 137
  • [43] Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2
    Sun, Yi-Sheng
    Zhou, Jing-Jing
    Zhu, Han-Ping
    Xu, Fang
    Zhao, Wen-Bin
    Lu, Hang-Jing
    Wang, Zhen
    Chen, Shu-Qing
    Yao, Ping-Ping
    Jiang, Jian-Min
    Zhou, Zhan
    VIRUSES-BASEL, 2021, 13 (10):
  • [44] Inactivated vaccine for SARS-CoV-2
    Emma Risson
    Nature Reviews Immunology, 2020, 20 : 353 - 353
  • [45] SARS-CoV-2 mucosal vaccine
    Stephanie Houston
    Nature Immunology, 2023, 24 : 1 - 1
  • [46] SARS-CoV-2 mucosal vaccine
    Houston, Stephanie
    NATURE IMMUNOLOGY, 2023, 24 (01) : 1 - 1
  • [47] A VACCINE AGAINST SARS-COV-2
    Passi, Gouri Rao
    INDIAN PEDIATRICS, 2020, 57 (06) : 593 - 593
  • [48] In Pursuit of a SARS-CoV-2 Vaccine
    Johnson, Alton R.
    McDonald, Adam R.
    Malay, D. Scot
    JOURNAL OF FOOT & ANKLE SURGERY, 2020, 59 (06): : 1133 - 1134
  • [49] Inactivated vaccine for SARS-CoV-2
    Risson, Emma
    NATURE REVIEWS IMMUNOLOGY, 2020, 20 (6) : 353 - 353
  • [50] Russian SARS-CoV-2 vaccine
    Caddy, Sarah
    BMJ-BRITISH MEDICAL JOURNAL, 2020, 370